Natera multi-cancer early detection assay

Overview

1. 9 Oct 2026DesignationUS

   FDA Breakthrough Device designation for Natera's multi-cancer early detection assay (company announcement) source

• Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
• A Breakthrough designation speeds FDA review; it is not an approval and says nothing about benefit.
• What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).